«One might expect
Accelerated Approval confirmatory trials to be much more rigorous than the pre-approval trials,» said Aaron S. Kesselheim, MD, JD, MPH, of the BWH Division of Pharmacoepidemiology and Pharmacoeconomics and senior author of the study.